PI3K Pathway Activation and Drug Resistance in HER2-Positive Breast Cancer
Author Information
Author(s): Wang Leiping, Zhang Qunling, Zhang Jian, Sun Si, Guo Haiyi, Jia Zhen, Wang Biyun, Shao Zhimin, Wang Zhonghua, Hu Xichun
Primary Institution: Fudan University Shanghai Cancer Center
Hypothesis
The study explores the relationship between PI3K pathway activation and the sensitivity to lapatinib in HER2-positive metastatic breast cancer patients.
Conclusion
PI3K pathway activation may lead to drug resistance to lapatinib and trastuzumab.
Supporting Evidence
- PIK3CA mutations were found in 12.3% of patients.
- PTEN loss was detected in 31.6% of patients.
- Patients with PI3K pathway activation had a lower clinical benefit rate of 36.4% compared to 68.6% in those without activation.
- The overall response rate was 9.1% for patients with activation versus 31.4% for those without.
- PI3K pathway activation correlated with a shorter median progression-free survival of 4.5 months.
Takeaway
This study found that some breast cancer patients have changes in their genes that make their treatment less effective.
Methodology
The study involved 67 HER2-positive metastatic breast cancer patients treated with lapatinib and capecitabine, with tumor specimens analyzed for PI3K pathway status.
Limitations
The study had a relatively small sample size and focused only on specific mutations.
Participant Demographics
Median age of participants was 49 years, with a range from 26 to 75 years.
Statistical Information
P-Value
0.017
Confidence Interval
95% CI, 5.7-7.3 months
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website